{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:41:07Z","timestamp":1787071267053,"version":"build-2736575974"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.4103\/sjg.sjg_245_25","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T13:00:21Z","timestamp":1762347621000},"page":"66-78","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Cost calculation model of introducing Upadacitinib and Risankizumab for adult ulcerative colitis and Crohn\u2019s disease in the Kingdom of Saudi Arabia"],"prefix":"10.4103","volume":"32","author":[{"given":"Mahmoud H.","family":"Mosli","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulelah A.","family":"Almutairdi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology and Hepatology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia"},{"name":"College of Medicine, Alfaisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah M.","family":"Alshahrani","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Khamis Mushayet Military Hospital, Khamis Mushayet, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman M.","family":"Alkhurmi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gastroenterology Division, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad N.","family":"Fasseeh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Alexandria University, Alexandria, Egypt"},{"name":"Department of Health Economics, Syreon Middle East, Alexandria, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali M.","family":"Anwar","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, AbbVie Biopharmaceuticals GmbH, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bandar M.","family":"Alharbi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Prince Sultan Military Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esraa S.","family":"Altawil","sequence":"additional","affiliation":[{"name":"Corporate Pharmacy Service, Pharmaceutical Care Division, King Saud University Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haneen J.","family":"Alshareef","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, King Abdullah Medical City, Makkah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussain A.","family":"Alqasim","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, King Fahad Specialist Hospital, Dammam, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibtisam H.","family":"Alharbi","sequence":"additional","affiliation":[{"name":"Pharmacoeconomic Center, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kareem A.","family":"El-Fass","sequence":"additional","affiliation":[{"name":"Department of Health Economics, Syreon Middle East, Alexandria, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layla N.","family":"Alanizy","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, King Fahd Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayd A.","family":"Almehizia","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia"},{"name":"College of Pharmacy, Alfaisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rok","family":"Hren","sequence":"additional","affiliation":[{"name":"Department of Health Economics, Syreon Research Institute, Budapest, Hungary"},{"name":"Department of Physics, Institute of Mathematics, Physics, and Mechanics, Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael K.","family":"Iskandarani","sequence":"additional","affiliation":[{"name":"Market Access Department, AbbVie Biopharmaceuticals GmbH, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana A.","family":"Alabdulkarim","sequence":"additional","affiliation":[{"name":"Drug Policy and Economic Center, National Guard Health Affairs, Riyadh, Saudi Arabia"},{"name":"Doctoral School of Applied Informatics and Applied Mathematics, \u00d3buda University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"R1-20260108","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.pharep.2014.04.005","article-title":"Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases","volume":"66","author":"Sobczak","year":"2014","journal-title":"Pharmacol Rep"},{"key":"R3-20260108","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R4-20260108","doi-asserted-by":"crossref","first-page":"e065186","DOI":"10.1136\/bmjopen-2022-065186","article-title":"Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: A systematic analysis based on the Global Burden of Disease Study 2019","volume":"13","author":"Rui","year":"2023","journal-title":"BMJ Open"},{"key":"R5-20260108","doi-asserted-by":"crossref","first-page":"100104","DOI":"10.1016\/j.crphar.2022.100104","article-title":"Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?","volume":"3","author":"Juillerat","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"R6-20260108","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"issue":"(Suppl 1)","key":"R7-20260108","first-page":"S1","article-title":"Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease","volume":"29","author":"Mosli","year":"2022","journal-title":"Saudi J Gastroenterol"},{"key":"R8-20260108","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.cgh.2022.10.029","article-title":"Comparative safety and effectiveness of biologic therapy for Crohn's disease: A CA-IBD cohort study","volume":"21","author":"Singh","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R9-20260108","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/apt.16445","article-title":"Systematic review: Societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents","volume":"54","author":"van Linschoten","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"(Supplement_1)","key":"R10-20260108","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jcag\/gwac036.169","article-title":"A169 the direct costs of inflammatory bowel disease in Canada: A population-based analysis of historical and current costs","volume":"6","author":"Coward","year":"2023","journal-title":"J Can Assoc Gastroenterol"},{"key":"R11-20260108","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/14737167.2023.2160322","article-title":"Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-na\u00efve and biologic-experienced patients with ulcerative colitis in France","volume":"23","author":"Oppe","year":"2023","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"R12-20260108","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000518003","article-title":"Incidence, prevalence, and clinical epidemiology of inflammatory bowel disease in the Arab world: A systematic review and meta-analysis","volume":"6","author":"Mosli","year":"2021","journal-title":"Inflamm Intest Dis"},{"key":"R14-20260108","doi-asserted-by":"crossref","first-page":"276","DOI":"10.5144\/0256-4947.2012.276","article-title":"Inflammatory bowel disease in Saudi Arabia: A hospital-based clinical study of 312 patients","volume":"32","author":"Fadda","year":"2012","journal-title":"Ann Saudi Med"},{"key":"R15-20260108","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12962-019-0194-3","article-title":"Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia","volume":"17","author":"AlRuthia","year":"2019","journal-title":"Cost Eff Resour Alloc"},{"key":"R16-20260108","first-page":"495","article-title":"Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: A systematic review","volume":"44","author":"Khan","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"R17-20260108","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s11938-020-00302-1","article-title":"Evidence supporting high-dose use of biologics in clinical practice","volume":"18","author":"Shannahan","year":"2020","journal-title":"Curr Treat Options Gastro"},{"key":"R19-20260108","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(22)00778-4","article-title":"Upadacitinib for ulcerative colitis","volume":"399","author":"Ananthakrishnan","year":"2022","journal-title":"Lancet"},{"issue":"(Supplement_1)","key":"R20-20260108","doi-asserted-by":"crossref","first-page":"i707","DOI":"10.1093\/ecco-jcc\/jjac190.0710","article-title":"P580 Upadacitinib is effective and safe for ulcerative colitis: Prospective real-world experience","volume":"17","author":"Friedberg","year":"2023","journal-title":"J Crohns Colitis"},{"issue":"(7 Suppl 2)","key":"R21-20260108","first-page":"12","article-title":"Highlights in ulcerative colitis from digestive disease week 2022: Commentary","volume":"18","author":"Rubin","year":"2022","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"R22-20260108","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2147\/DDDT.S379446","article-title":"Clinical evaluation of risankizumab in the treatment of adults with moderately to severely active Crohn's disease: Patient selection and reported outcomes","volume":"17","author":"Horst","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"R23-20260108","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s12325-023-02457-6","article-title":"Dose escalation patterns of advanced therapies in Crohn's disease and ulcerative colitis: A systematic literature review","volume":"40","author":"Panaccione","year":"2023","journal-title":"Adv Ther"},{"key":"R24-20260108","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JHL.S352500","article-title":"An adaptation of the RAND\/UCLA modified Delphi panel method in the time of COVID-19","volume":"14","author":"Broder","year":"2022","journal-title":"J Healthc Leadersh"},{"key":"R25-20260108","doi-asserted-by":"crossref","first-page":"e32829","DOI":"10.1097\/MD.0000000000032829","article-title":"Use of Delphi in health sciences research: A narrative review","volume":"102","author":"Shang","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"R26-20260108","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1007\/s10620-019-05867-1","article-title":"Biologic use patterns and predictors for non-persistence and switching of biologics in patients with inflammatory bowel disease: A nationwide population-based study","volume":"65","author":"Jung","year":"2020","journal-title":"Dig Dis Sci"},{"key":"R27-20260108","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/ibd\/izz001","article-title":"Real-world pattern of biologic use in patients with inflammatory bowel disease: Treatment persistence, switching, and importance of concurrent immunosuppressive therapy","volume":"25","author":"Chen","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"R28-20260108","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1007\/s10620-023-07897-2","article-title":"Ustekinumab versus anti-tumour necrosis factor alpha agents as second-line biologics in Crohn's disease","volume":"68","author":"Eriksson","year":"2023","journal-title":"Dig Dis Sci"},{"key":"R29-20260108","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1080\/00365521.2023.2173988","article-title":"Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: A population-based Danish cohort study 2015-2020","volume":"58","author":"Jensen","year":"2023","journal-title":"Scand J Gastroenterol"},{"key":"R30-20260108","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/apt.16436","article-title":"Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: Real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study","volume":"54","author":"Ko","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"R31-20260108","doi-asserted-by":"crossref","first-page":"otac050","DOI":"10.1093\/crocol\/otac050","article-title":"Effectiveness and safety of tofacitinib in the management of ulcerative colitis: A Brazilian observational multicentric study","volume":"5","author":"Perin","year":"2022","journal-title":"Crohns Colitis 360"},{"key":"R32-20260108","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2147\/CEOR.S391413","article-title":"Systematic literature review of real-world evidence on dose escalation and treatment switching in ulcerative colitis","volume":"15","author":"Singh","year":"2023","journal-title":"Clinicoecon Outcomes Res"},{"key":"R33-20260108","doi-asserted-by":"crossref","first-page":"otab076","DOI":"10.1093\/crocol\/otab076","article-title":"Persistence, dosing, and other treatment patterns among Crohn's disease patients initiating biologics in United States","volume":"3","author":"Teeple","year":"2021","journal-title":"Crohns Colitis 360"},{"key":"R34-20260108","article-title":"United Nations. World Population Prospects - Population Division - United Nations","year":"2024"},{"key":"R35-20260108","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/1319-3767.105915","article-title":"Emerging inflammatory bowel disease in saudi outpatients: A report of 693 cases","volume":"19","author":"Al-Mofleh","year":"2013","journal-title":"Saudi J Gastroenterol"},{"key":"R36-20260108","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/00365521.2020.1726445","article-title":"Treatment patterns for biologics in ulcerative colitis and Crohn's disease: A Danish Nationwide Register Study from 2003 to 2015","volume":"55","author":"Alulis","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"R37-20260108","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/ibd\/izab015","article-title":"Re-induction with intravenous Ustekinumab in patients with Crohn's disease and a loss of response to this therapy","volume":"28","author":"Bermejo","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"R38-20260108","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/MIB.0000000000000608","article-title":"Mortality trends in Crohn's disease and ulcerative colitis","volume":"22","author":"Bitton","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"R39-20260108","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1080\/14712598.2021.1981855","article-title":"One-year effectiveness and safety of ustekinumab in ulcerative colitis: A multicenter real-world study from Italy","volume":"21","author":"Chiappetta","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"R40-20260108","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.cgh.2018.04.040","article-title":"Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases","volume":"16","author":"Dreesen","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R41-20260108","doi-asserted-by":"crossref","first-page":"867293","DOI":"10.3389\/fmed.2022.867293","article-title":"Clinico-epidemiological characteristics of patients with inflammatory bowel disease in Egypt: A nationwide multicenter study","volume":"9","author":"Elbadry","year":"2022","journal-title":"Front Med"},{"key":"R42-20260108","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/ecco-jcc\/jjab093","article-title":"Long-term safety and efficacy of Risankizumab treatment in patients with Crohn's disease: Results from the phase 2 open-label extension study","volume":"15","author":"Ferrante","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"(Supplement_1)","key":"R43-20260108","doi-asserted-by":"crossref","first-page":"i414","DOI":"10.1093\/ecco-jcc\/jjab232.557","article-title":"P430 Longer-term tofacitinib effectiveness for the treatment of ulcerative colitis: Two-year outcomes from a UK observational cohort study","volume":"16","author":"Honap","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"(Supplement_1)","key":"R44-20260108","doi-asserted-by":"crossref","first-page":"i383","DOI":"10.1093\/ecco-jcc\/jjab232.510","article-title":"P383 Ustekinumab as an opportunity for refractory ulcerative colitis patients","volume":"16","author":"Iborra","year":"2022","journal-title":"J Crohns Colitis"},{"key":"R45-20260108","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.dld.2018.07.040","article-title":"Effectiveness and safety of vedolizumab for maintenance treatment in inflammatory bowel disease\u2014The Israeli real world experience","volume":"51","author":"Kopylov","year":"2019","journal-title":"Dig Liver Dis"},{"key":"R46-20260108","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/apt.15784","article-title":"Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy","volume":"52","author":"Kopylov","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"R47-20260108","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/MIB.0000000000001074","article-title":"Long-term maintenance of clinical, endoscopic, and radiographic response to Ustekinumab in moderate-to-severe Crohn's disease","volume":"23","author":"Ma","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"R49-20260108","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1080\/03007995.2022.2071041","article-title":"Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: A pooled study of three United States claim databases","volume":"38","author":"Sah","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"R50-20260108","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjab012","article-title":"Long-term efficacy and safety of ozanimod in moderately to severely active ulcerative colitis: Results from the open-label extension of the randomized, phase 2 TOUCHSTONE study","volume":"15","author":"Sandborn","year":"2021","journal-title":"J Crohns Colitis"},{"key":"R51-20260108","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/ecco-jcc\/jjx144","article-title":"Anti-TNF re-induction is as effective, simpler, and cheaper compared with dose interval shortening for secondary loss of response in Crohn's disease","volume":"12","author":"Srinivasan","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R52-20260108","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1097\/MIB.0000000000000146","article-title":"Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease","volume":"20","author":"Stein","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"R53-20260108","first-page":"645","article-title":"Efficacy of Ustekinumab intensification and re-induction in Crohn's disease patients with insufficient or loss of response","volume":"8","year":"2019","journal-title":"UEG Week 2019 Poster Presentations"},{"key":"R54-20260108","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/apt.14430","article-title":"Market share and costs of biologic therapies for inflammatory bowel disease in the USA","volume":"47","author":"Yu","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R55-20260108","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/a17120546","article-title":"Tradeoffs when building and running cohort and patient-level markov simulation models","volume":"17","author":"Nagy","year":"2024","journal-title":"Algorithms"},{"key":"R56-20260108","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis-principles of good practice: Report of the ISPOR 2012 budget impact analysis good practice II task force","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Health"},{"key":"R57-20260108","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/1319-3767.105915","article-title":"Emerging inflammatory bowel disease in Saudi outpatients: A report of 693 cases","volume":"19","author":"Al-Mofarreh","year":"2013","journal-title":"Saudi J Gastroenterol"},{"key":"R58-20260108","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1186\/s12913-022-08683-y","article-title":"Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries","volume":"22","author":"Yoo","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"R59-20260108","first-page":"253","article-title":"Budget impact of adding vedolizumab to a health plan formulary as another first-line biologic option for ulcerative colitis and Crohn's disease","volume":"11","author":"Wilson","year":"2018","journal-title":"Am Health Drug Benefits"},{"key":"R60-20260108","article-title":"Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: Systematic review and network meta-analysis","author":"Burr","year":"2021","journal-title":"Gut"},{"key":"R61-20260108","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/gutjnl-2022-328052","article-title":"Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: Systematic review and network meta-analysis","volume":"72","author":"Barberio","year":"2023","journal-title":"Gut"},{"key":"R62-20260108","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: A systematic review and network meta-analysis","volume":"6","author":"Singh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R63-20260108","doi-asserted-by":"crossref","first-page":"1475222","DOI":"10.3389\/fphar.2024.1475222","article-title":"Systematic review and bayesian network meta-analysis: Comparative efficacy and safety of six commonly used biologic therapies for moderate-to-severe Crohn's disease","volume":"15","author":"Su","year":"2025","journal-title":"Front Pharmacol"},{"key":"R64-20260108","doi-asserted-by":"crossref","first-page":"1481678","DOI":"10.3389\/fphar.2024.1481678","article-title":"Network meta-analysis of efficacy and safety of drugs for the treatment of moderate to severe ulcerative colitis","volume":"15","author":"Zhang","year":"2025","journal-title":"Front Pharmacol"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_245_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:43:54Z","timestamp":1787067834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_245_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_245_25","relation":{},"ISSN":["1319-3767","1998-4049"],"issn-type":[{"value":"1319-3767","type":"print"},{"value":"1998-4049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"2025-07-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}